Cerezyme
Named-patient access overview. Cerezyme is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cerezyme (imiglucerase) is the long-established enzyme replacement therapy for Gaucher disease, manufactured by Sanofi (formerly Genzyme), approved by the US Food and Drug Administration in 1994. It is a recombinant glucocerebrosidase delivered as an intravenous infusion every two weeks, typically dosed at 60 units per kilogram body weight for symptomatic type 1 Gaucher disease, with downward titration based on clinical response and disease control.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cerezyme
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cerezyme is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Cerezyme in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cerezyme
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.